The Challenge: Endolysosomal trapping of macromolecules

One of the greatest challenges for efficacy of macromolecule therapeutics that act on an intracellular level, is delivery into key cells. Macromolecule therapeutics nowadays rely on receptor-mediated endocytosis into the endosomal compartment. The endo-lysosomal membranes, however, prohibit efficient cytoplasmic access of such foreign substances. The therapeutic efficacy of such drugs is therefore highly dependent on endo-lysosomal vesicles degradation.
Cytosolic delivery of macromolecule therapeutics requires incredibly challenging technical optimizations or specialized drug delivery platforms. For most oligonucleotide-based therapeutics, delivery remains an unsolved problem and exposes a significant need for the development of novel delivery mechanisms.

Our Approach: ENDOSCAPE®

At Sapreme, we are developing improved macromolecule delivery mechanisms by circumventing endosomal entrapment. Our ENDOSCAPE® platform is based on compounds which can release trapped cargo from the endo-lysosomal membranes, improving the therapeutic window and enabling access to intracellular targets with minimal toxicity.
By binding our technology to antibody-conjugated toxins and oligonucleotides, our goal is to enhance target engagement and improve therapeutic efficacy without limitation to biologic modality or indication.

If you are a talented individual interested in contributing to our mission, please send your resume to 

info@sapreme-technologies.com